CLINICAL TRIALS

PARI Pharma products are currently being used in more than 20 clinical trials for new medications delivered by nebulizer. PARI Pharma has a proven track record for device supply and coordination of clinical trials with pharma companies. In addition, PARI Pharma products are listed in the package insert for many current medications including those indicated with an * below:

  • Perforomist (Dey) for COPD
  • Brovana® (Sepracor) for COPD
  • Pulmozyme® (Genentech) for cystic fibrosis cystic fibrosis
    Genetic disorder that affects most critically the lungs, leading to thick, viscous secretions.
    <
  • Pulmicort Respules® (AstraZeneca) for asthma asthma
    Asthma is a common chronic inflammatory airway disease, characterized by variable and recurring symptoms, reversible airflow obstruction and bronchospasm.
  • TOBI® (Novartis) for cystic fibrosis cystic fibrosis
    Genetic disorder that affects most critically the lungs, leading to thick, viscous secretions.
  • DuoNeb® (Dey) for COPD, asthma asthma
    Asthma is a common chronic inflammatory airway disease, characterized by variable and recurring symptoms, reversible airflow obstruction and bronchospasm.
  • AccuNeb® (Dey) for asthma asthma
    Asthma is a common chronic inflammatory airway disease, characterized by variable and recurring symptoms, reversible airflow obstruction and bronchospasm.
  • Xopenex® (Sepracor) for asthma asthma
    Asthma is a common chronic inflammatory airway disease, characterized by variable and recurring symptoms, reversible airflow obstruction and bronchospasm.
  • Cayston® (Gilead) for CF